DX-002 / NewOpp Biopharma - LARVOL DELTA

A fully human agonistic antibody against a unique epitope on TREM1 demonstrates immune stimulatory activities both in vitro and in vivo (AACR 2025) - "In vivo, DX002 exhibits significant tumor growth inhibition activity in MC38 syngeneic model in human TREM1 transgenic mice. Taken together, the TREM1 agonistic antibody DX002 is shown to be active both in vitro and in vivo."

Preclinical • Oncology

DX-002, a dual EP2 and EP4 antagonist, alters the tumor microenvironment to enhance tumor immunogenicity and responses to immune checkpoint inhibitors (AACR 2023) - "In addition, DX-002 also provided significant synergistical effect for tumor regression in combination with anti-PD1 in both immune checkpoint inhibitor insensitive and sensitive models, in association with increased tumor infiltration of CD8+ T cells. Based on its in vitro and in vivo profiles along with other properties, DX-002 is being profiled as a development candidate as a potential cancer immunotherapeutic agent."

Biomarker • Checkpoint inhibition • Tumor microenvironment • Oncology • CD8 • IFNG